IP Library › Granted Patent US 12,194,090
Granted Patent B2
US 12,194,090 · App. 18/060,401 · Granted Jan 14, 2025

Tetanus vaccine platform for embedding COVID-19 vaccine

Inventors: Bal Ram Singh (Dartmouth, MA); Kruti Patel (North Dartmouth, MA); Raj Kumar (Dartmouth, MA)
Assignee: PRIME BIO, INC.
A61K39/215A61K39/39A61P31/14A61K2039/542A61K2039/55544A61K2039/6037C12N2770/20022C12N2770/20034C12N2770/20071
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,194,090
App. No.
18/060,401
Granted
Jan 14, 2025
Kind
B2
Abstract

A recombinant SARS-CoV2 protein-based vaccine, and method of immunizing, is developed by either embedding the epitopes/domains, or chemically attaching, to an already established vaccine candidate, such as a detoxified recombinant tetanus neurotoxin (DrTeNT), to develop a novel vaccine to immunize against SARS-CoV2. The developed vaccine will have three novel contributions compared to the present vaccine technology; a) providing a novel and very effective vaccine platform; b) priming with DrTeNT will prepare the host immune system for better response; and c) oral delivery of the vaccine candidate with a group of neurotoxin binding proteins (NAPs) from Clostridium sp. A Detoxified recombinant tetanus neurotoxin (DrTeNT) is prepared by mutation of the active site amino acid residues is an effective vaccine candidate, and is to be used for embedding epitopes of SARS-CoV-2 virus protein for vaccination against Covid-19. DrTeNT is a risk-free vaccine, free of formalin or any other chemical adjuvants.

Claims (18)

1. A recombinant or a conjugate protein vaccine composition for treating or preventing a COVID-19 infection, comprising:

a) one or more proteins, or a variant thereof, comprising detoxified forms of a tetanus neurotoxin (DrTeNT);

b) wherein the one or more proteins, or the variant thereof, are embedded with or chemically attached to one or more epitopes and/or domains encoding a targeted immunogenic peptide derived from a Severe Acute Respiratory Syndrome (SARS-COV2) disease or a variant thereof, to create a Tetanus COVID (TC2) recombinant protein vaccine, or a TC2 or DrTeNT conjugate protein vaccine;

c) wherein said recombinant or conjugate protein vaccine composition comprises the one or more proteins having at least 90% sequence identity to the full length of SEQ ID NOS: 6 or 7; and

d) wherein said recombinant or conjugate protein vaccine composition is able to activate memory cells against Severe Acute Respiratory Syndrome (SARS-COV2) without an adverse immune response while excluding formaldehyde.

2. The vaccine composition of claim 1 , wherein the conjugate protein vaccine comprises chemically attaching the one or more DrTeNT or TC 2 or any variant thereof to the one or more epitopes and/or domains comprising a receptor binding domain (RBD) and/or a S1 domain and/or a S2 domain of the SARS-COV2 to create a hybrid protein.

3. The vaccine composition of claim 1 , wherein the vaccine is a recombinant protein vaccine.

4. The vaccine composition of claim 1 , wherein the vaccine composition is able to immunize a human or a non-human mammal against SARS -CoV2 infection.

5. The vaccine composition of claim 1 , wherein the disease encodes a targeted protein comprising S1 and RBD epitopes that are derived from the SARS-COV2virus as a source material.

6. The vaccine composition of claim 1 , further comprises a second vaccine composition wherein the epitopes are derived from one or more pathogen proteins associated with viral diseases comprising: flu, dengue, HIV, and variants thereof.

7. The vaccine composition of claim 1 , wherein the detoxified form of the vaccines contains one or more modifications comprising deletions, insertions, or substitutions of nucleotide or amino acid sequences in the embedded SARS-COV2epitopes.

8. The vaccine composition of claim 1 , further comprising a formulating agent for oral, sublingual, and/or nasal delivery by adding one or more neurotoxin associated proteins (NAPs) derived from a botulinum neurotoxin (BoNT) produced by a Clostridium.

9. The vaccine composition of claim 1 , further comprising an adjuvant comprising one or more of: alum, polylactic acid, polyglycolic acid, Vitamin E, and colloidal particle.

10. The vaccine composition of claim 1 , comprising at least 90% sequence identity to one or more of SEQ ID NOS: 3, 5.

11. The vaccine composition of claim 1 , comprising at least 90% sequence identity to SEQ ID NO: 6.

12. The vaccine composition of claim 1 , wherein the inserted epitopes are between 4 K and 44 P; 294 G and 334 G; 533 G and 573 N; 731 G and 771 G; 858 G and 898 Q; 970 G and 1010 K of SEQ ID NO: 6.

13. The vaccine composition of claim 2 , wherein DrTeNT is attached chemically to the one or more epitopes and/or domains comprising the receptor binding domain (RBD) and the S1 domain and the S2 domain of the SARS-COV2 to create a hybrid protein.

14. The vaccine composition of claim 13 , comprising at least 90% sequence identity to SEQ ID NO: 7.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 4, 2022
From: SINGH, BAL RAM; PATEL, KRUTI; KUMAR, RAJ
To: PRIME BIO, INC.
Reel/Frame 061964/0812 →
Continuity (3)
Continuation PCTUS2021044054 · Jul 30, 2021
Provisional Application 63032544 · May 30, 2020
Related Publication 20230201332A1 · Jun 29, 2023
References Cited (55)
US 1104009A · Seguin · 1914 [cited by applicant]
US 6699966B1 · Singh et al. · 2004 [cited by applicant]
US 11040090B2 · Singh · 2021 [cited by applicant]
US 11389497B2 · Singh et al. · 2022 [cited by applicant]
US 11771752B2 · Singh · 2023 [cited by applicant]
US 20180014722A1 · Lee et al. · 2018 [cited by applicant]
US 20180161406A1 · Singh · 2018 [cited by applicant]
US 20190076518A1 · Singh · 2019 [cited by examiner]
US 20210121542A1 · Singh et al. · 2021 [cited by applicant]
US 20210346292A1 · Singh et al. · 2021 [cited by applicant]
US 20220288173A1 · Singh et al. · 2022 [cited by applicant]
US 20220390461A1 · Singh et al. · 2022 [cited by applicant]
WO 2018118974 · 2019 [cited by examiner]
WO WO2019118974A4 · 2019 [cited by applicant]
WO WO2021248145A2 · 2021 [cited by applicant]
Zhao et al (Viral Immunol. 2006. 19(3): 518-524). [cited by examiner]
Greenspan et al (Nature Biotechnology 7: 936-937, 1999). [cited by examiner]
Chothia et al (The EMBO Journal, 1986, 5/4:823-26). [cited by examiner]
Mikayama et al. (Nov. 1993. Proc.Natl.Acad.Sci. USA, vol. 90 : 10056-10060). [cited by examiner]
Rudinger et al. (Jun. 1976. Peptide Hormones. Biol. Council. pp. 5-7). [cited by examiner]
Thanh Le T, Andreadakis Z, Kumar A, Gomez Roman R, Tollefsen S, Saville M, Mayhew S. 2020. The COVID-19 vaccine development landscape. Nat Rev Drug Discov 19:305-306. [cited by applicant]
Hotez PJ, Bottazzi ME, Corry DB. 2020. The potential role of Th17 immune responses in coronavirus immunopathology and vaccine-induced immune enhancement. Microbes Infect doi:10.1016/j.micinf.2020.04.005. [cited by applicant]
Smatti MK, Al Thani AA, Yassine HM. 2018. Viral-Induced Enhanced Disease Illness. Front Microbiol 9:2991. [cited by applicant]
Konig MF, Powell MA, Staedtke V, Bai R-Y, Thomas DL, Fischer NM, Huq S, Khalafallah AM, Koenecke A, Xiong R, Mensh B, Papadopoulos N, Kinzler KW, Vogelstein B, Vogelstein JT, Athey S, Zhou S, Bettegowda C. 2020. Prevent… [cited by applicant]
Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, Hlh Across Speciality Collaboration UK. 2020. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 395:1033-1034. [cited by applicant]
Jose RJ, Manuel A. 2020. COVID-19 cytokine storm: the interplay between inflammation and coagulation. Lancet Respir Med. [cited by applicant]
Deinhardt K, Schiavo G. 2005. Endocytosis and retrograde axonal traffic in motor neurons. Biochem Soc Symp:139-50. [cited by applicant]
Schiavo G, Rossetto O, Santucci A, DasGupta BR, Montecucco C. 1992. Botulinum neurotoxins are zinc proteins. J Biol Chem 267:23479-83. [cited by applicant]
Lacy DB, Stevens RC. 1999. Sequence homology and structural analysis of the clostridial neurotoxins. J Mol Biol 291:1091-104. [cited by applicant]
Singh BR, Chang T-W, Kukreja R, Cai S. 2014. The Botulinum Neurotoxin Complex and the Role of Ancillary Proteins, p. 69-101. In Foster KA (ed), Molecular Aspects of Botulinum Neurotoxin. Springer New York, New York, NY. [cited by applicant]
Schiavo G, Matteoli M, Montecucco C. 2000. Neurotoxins affecting neuroexocytosis. Physiol Rev 80:717-66. [cited by applicant]
Ravichandran E, Janardhanan P, Patel K, Riding S, Cai S, Singh BR. 2016. In Vivo Toxicity and Immunological Characterization of Detoxified Recombinant Botulinum Neurotoxin Type A. Pharm Res 33:639-52. [cited by applicant]
Ghosal KJ, Patel K, Singh BR, Hale ML. 2018. Role of critical elements in botulinum neurotoxin complex in toxin routing across intestinal and bronchial barriers. PLoS One 13:e0199524. [cited by applicant]
PCT/US2021/044054 International Preliminary Report/Demand, forms 416, 409, mailed Jul. 25, 2022. [cited by applicant]
PCT/US2021/044054 International Search Report, form 220/210, mailed Jan. 21, 2022. [cited by applicant]
Williams GA, Koenen ME, Havenaar R, Wheeler P, Gowtage S, Lesellier S, Chambers MA. 2019. Survival of [cited by applicant]
Sanchez JL, Trofa AF, Taylor DN, Kuschner RA, DeFraites RF, Craig SC, Rao MR, Clemens JD, Svennerholm AM, Sadoff JC, et al. 1993. Safety and immunogenicity of the oral, whole cell/recombinant B subunit cholera vaccine i… [cited by applicant]
Kumar R, Chang, T. W., and Singh, B. R. 2017. Evolutionary traits of toxins. Springer Netherlands. [cited by applicant]
Singh BR, Li B, Read D. 1995. Botulinum versus tetanus neurotoxins: why is botulinum neurotoxin but not tetanus neurotoxin a food poison? Toxicon 33:1541-7. [cited by applicant]
Yang W, Lindo P, Riding S, Chang TW, Cai S, Van T, Kukreja R, Zhou Y, Vasa K, Singh BR. 2008. Expression, purification and comparative characterisation of enzymatically deactivated recombinant botulinum neurotoxin type … [cited by applicant]
Sakaguchi G. 1983. Clostridium botulinum toxins. Pharmacol Ther 19:165-94. [cited by applicant]
Costantino HR, Schwendeman SP, Griebenow K, Klibanov AM, Langer R. 1996. The secondary structure and aggregation of lyophilized tetanus toxoid. J Pharm Sci 85:1290-3. [cited by applicant]
Belouzard S, Millet JK, Licitra BN, Whittaker GR. 2012. Mechanisms of coronavirus cell entry mediated by the viral spike protein. Viruses 4:1011-33. [cited by applicant]
Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, Graham BS, McLellan JS. 2020. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367:1260-1263. [cited by applicant]
Matsuyama S, Ujike M, Morikawa S, Tashiro M, Taguchi F. 2005. Protease-mediated enhancement of severe acute respiratory syndrome coronavirus infection. Proc Natl Acad Sci U S A 102:12543-7. [cited by applicant]
Robson B. 2020. COVID-19 Coronavirus spike protein analysis for synthetic vaccines, a peptidomimetic antagonist, and therapeutic drugs, and analysis of a proposed achilles' heel conserved region to minimize probability … [cited by applicant]
Robson B. 2020. Computers and viral diseases. Preliminary bioinformatics studies on the design of a synthetic vaccine and a preventative peptidomimetic antagonist against the SARS-COV-2 (2019-nCOV, COVID-19) coronavirus… [cited by applicant]
Grifoni A, Sidney J, Zhang Y, Scheuermann RH, Peters B, Sette A. 2020. Candidate targets for immune responses to 2019-Novel Coronavirus (nCoV): sequence homology- and bioinformatic-based predictions. [cited by applicant]
Ahmed SF, Quadeer AA, McKay MR. 2020. Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies. Viruses 12. [cited by applicant]
Shang J, Ye G, Shi K, Wan Y, Luo C, Aihara H, Geng Q, Auerbach A, Li F. 2020. Structural basis of receptor recognition by SARS-CoV-2. [cited by applicant]
Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. 2020. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science 367:1444-1448. [cited by applicant]
Yao B, Zhang L, Liang S, Zhang C. 2012. SVMTriP: a method to predict antigenic epitopes using support vector machine to integrate tri-peptide similarity and propensity. PLoS One 7:e45152. [cited by applicant]
Zhao et al., 2006. “Immunization of Mice with a DNA Vaccine Based on Severe Acute Respiratory Syndrome Coronavirus Spike Protein Fragment 1”, Viral Immunology. vol. 19. No. 3, pp. 518-524. [cited by applicant]
KB Patel, S Cai, M Adler, B K. Singh, V S. Parmar, BR Singh, Nov. 2018, “Natural Compounds and Their Analogues as Potent Antidotes against the Most Poisonous Bacterial Toxin”, Applied and Environmental Microbiology. vol… [cited by applicant]
R Kukreja, BR Singh, “The botulinum toxin as a therapeutic agent: molecular and pharmacological insights”. .2015. Research and Reports in Biochemistry. Vo. 5, pp. 173-183. [cited by applicant]